Skip to main content
SpringerLink
Log in

Paclitaxel (Taxol®) Mechanisms of Resistance

  • Chapter
Drug Resistance

Part of the book series: Cancer Treatment and Research ((CTAR,volume 87))

Abstract

Paclitaxel (Taxol #®) is one of the most promising new anticancer agents developed in recent years [1]. Taxol® has been approved for the treatment of refractory ovarian [2,3] and breast cancer [4] in several countries, and has shown activity against after human malignancies, such as lung cancer head and neck cancer, esophageal cancer, hematological malignancies, and melanomas. However, even in patients with responding tumors, response rates have not been superior to 50%, and relapses have always been the case, indicating that (1) even among the sensitive tumor types, there are examples of cancers that are naturally resistant to Taxol therapy (and these tumors are defined as having intrinsic resistance or insensitivity to Taxol, and (2) treatment with Taxol inexorably leads to development of resistance to paclitaxel (and these tumors are defined as having acquired resistance to Taxol). An understanding of the mechanisms of intrinsic or acquired resistance of cancer cells to paclitaxel can result in (1) design of better therapeutic modalities (drug combinations, sequences, schedule of treatment) for the treatment of cancer patients; (2) development of appropriate experimental models that represent as closely as possible the clinical cause of paclitaxel insensitivity or resistance; and (3) identification of novel anticancer drugs, and in particular paclitaxel analogs, active against paclitaxel-resistant cancer cells. An agent active against such tumor cells in vitro and in vivo would, in fact, be an important candidate for clinical development.

TAXOL® is a registered trademark of Bristol-Myers Squibb Company. The approved generic name for the drug is paclitaxel.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Suffness M, Wall M (1995) Discovery and Development of Taxol. In Taxol, Science and Application. Boca Raton, FL: Ed. by M. Suffness CRC Press, pp 3–26.

    Google Scholar 

  2. Caldas C, McGuire WP (1993) Paclitaxel (Taxol) therapy in ovarian carcinoma. Semin Oncol 20:50–55.

    PubMed  CAS  Google Scholar 

  3. Ozols RF (1994) Treatment of ovarian cancer: Current status. Semin Oncol 21:1–9.

    PubMed  CAS  Google Scholar 

  4. Seidman AD, Reichman BS, Crown JPA, Yao T-J, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152–1159.

    PubMed  CAS  Google Scholar 

  5. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427.

    PubMed  CAS  Google Scholar 

  6. Childs S, Ling V (1994) The MDR superfamily of genes and its biological implications. In VT DeVita, S Hellman, SA Rosenberg, eds. Important Advances in Oncology. Philadelphia: JB Lippincot, pp 21–36.

    Google Scholar 

  7. Gupta RS (1983) Taxol resistant mutants of Chinese hamster ovary cells genetic biochemical and cross resistance studies. J Cell Physiol 114:137–144.

    PubMed  CAS  Google Scholar 

  8. Gupta RS (1985) Cross-resistant of vinblastine and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep 69:515–522.

    PubMed  CAS  Google Scholar 

  9. Schibler MJ, Cabrai F (1986) Taxol-dependent mutants of Chinese hamster ovary cells with alterations in a and ß-tubulin. J Cell Biol 102:1522–1531.

    PubMed  CAS  Google Scholar 

  10. Roy SN, Horwitz SB (1985) A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45:3856–3863.

    PubMed  CAS  Google Scholar 

  11. Greenberg LM, Lothstein L, Williams SS, Horwitz S (1988) Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cells lines. Proc Natl Acad Sci USA 85:3762–3766.

    Google Scholar 

  12. Long B, Wang L, Lorico A, Wang RCC, Brattain MG, Casazza AM (1991) Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51:5275–5284.

    PubMed  CAS  Google Scholar 

  13. Fairchild C (1992) Taxol in vitro cytotoxicity studies performed at Bristol-Myers Squibb. Bristol-Myers Squibb Internal Report 50323.

    Google Scholar 

  14. Choi K, Chen CJ, Kriegler M, Roninson IB (1988) An altered pattern of cross-resistance in multidrug-resistant cells results from spontaneous mutations in the mdrl P-gp gene. Cell 53:519–529.

    PubMed  CAS  Google Scholar 

  15. Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND, Roninson IB, Zhan Z, Kang Y-K, Giannakakov P, Villalba L, Walendowski E, Poruchynski M, Wilsom W, Bates S, Fojo T (1990) Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185 to Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 87:7225–7229.

    PubMed  CAS  Google Scholar 

  16. Cardarelli CO, Akesntijevich I, Pastan I, Gottesman MM (1995) Differential effects of Pglycoprotein inhibitors on NIHSTS cells transfected with wild type (G185) or mutant (V185) multidrug transporters. Cancer Res 55:1086–1091.

    PubMed  CAS  Google Scholar 

  17. Yang CPH, Mellado W, Horwitz SB (1988) Azidopine photoaffnity labeling of multidrug resistance-associated glycoproteins. Biochem Pharmacol 37:1417–1421.

    PubMed  CAS  Google Scholar 

  18. Yang CPH, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB (1989) Progesterone interacts with p-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264:782–788.

    PubMed  CAS  Google Scholar 

  19. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R (1992) Human p-glycoprotein transports Cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248–24252.

    PubMed  CAS  Google Scholar 

  20. Cabrai F, Sobel M, Gottesman M (1980) CHO mutants resistant to colchicine, colcemid or griseofulvine have an altered b-tubulin. Cell 20:29–36.

    Google Scholar 

  21. Schibler M, Cabrai F (1985) Maytansine-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin. Can J Biochem Cell Biol 63:503–510.

    PubMed  CAS  Google Scholar 

  22. Dumontet CM, Duran GE, Sikic BI (1995) Mechanisms of resistance to paclitaxel (Taxol, TAX) in human sarcoma mutants derived by single-step selection. Proc Am Assoc Cancer Res 36:320.

    Google Scholar 

  23. Zhan Z, Kang Y-K, Giannakakou P, et al. (1994) Tubulin expression and polymerization in normal tissues, human tumors and paclitaxel (PTX) selected ovarian and breast carcinoma cells. Proc Am Assoc Cancer Res 35:390.

    Google Scholar 

  24. Dumontet C, Jaffrezou J-P, Duran G, Jordan MA, Wilson L, Sikic B (1994) Resistance to paclitaxel (Taxol-R) in KPTA5 variants of K562 cells is associated with the overexpression of 5-beta isotype of tubulin. Blood 84:603A.

    Google Scholar 

  25. Cornell L, Peterson R, Johnston KA, Fairchild CR (1995) Selection and characterization of a paclitaxel resistant cell line which has a non-P-glycoprotein mediated mechanism of resistance. Proc Am Assoc Cancer Res 36:320.

    Google Scholar 

  26. Waud WR, Gilbert KS, Harrison Jr SD, Griswold Jr DP (1992) Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo. Cancer Chemother Pharmacol 31:255–257.

    PubMed  CAS  Google Scholar 

  27. Lee FYF, Fager K, Fairchild C, Carboni J (1995) In vivo resistance to paclitaxel in the murine Madison 109 lung carcinoma is acquired in two mechanistically distinct stages. Proc Am Assoc Cancer Res 36:319.

    Google Scholar 

  28. Pastan I, Willingham MC, Gottesman M (1991) Molecular manipulations of the multidrug transporter: A new role for transgenic mice. FASEB J 5:2523–2528.

    PubMed  CAS  Google Scholar 

  29. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW (1992) Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99–103.

    PubMed  CAS  Google Scholar 

  30. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48:4093–4100.

    PubMed  CAS  Google Scholar 

  31. Cabrai F, Abraham I, Gottesman MM (1981) Isolation of a taxol resistant Chinese hamster ovary cell mutant that has an alteration in alpha tubulin. Proc Natl Acad Sci USA 78:4388–4391.

    Google Scholar 

  32. Cabrai FR (1983) Isolation of Chines hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 97:22–29.

    Google Scholar 

  33. Cabrai F, Wible L, Brenner S, Brinkley BR (1983) Taxol-requiring mutant of Chinese hamster ovary cells with inpaired mitotic spindle assembly. J Cell Biol 97:30–39.

    Google Scholar 

  34. Cabrai F, Brady RC, Schibler MJ (1986) A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann NY Acad Sci 466:745–756.

    Google Scholar 

  35. Minotti AM, Barlow SB, Cabrai F (1991) Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987–3994.

    PubMed  CAS  Google Scholar 

  36. Rao S, Horwitz SB (1992) A multidrug resistance murine cell line is partially dependent on taxol for growth and has an increased tubulin content. Proc Am Assoc Cancer Res 33:461.

    Google Scholar 

  37. Haber M, Burkhart CA, Regl D, Madafiglio J, Noms MD, Horwitz SB (1995) Taxol resistance in murine J774.2 cells is associated with altered expression of specific beta-tubulin isotypes. Proc Am Assoc Cancer Res 36:318.

    Google Scholar 

  38. Ohta S, Nishio K, Kubuta N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M, Saijo N (1994) Characterization of a Taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85:290–297.

    PubMed  CAS  Google Scholar 

  39. Potier P (1989) The synthesis of navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16:2–4.

    PubMed  CAS  Google Scholar 

  40. Debal V, Allam N, Morjani H, Millot JM, Bragver D, Breillout F, Manfait M (1994) Characterization of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids. Br J Cancer 70:1118–1125.

    PubMed  CAS  Google Scholar 

  41. Jordan M, Toso R, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552–9556.

    PubMed  CAS  Google Scholar 

  42. Giannakakou P, Sackett D, Mickley L, Kang Y-K, Fojo AT (1995) Characterization of non-Pgp paclitaxel (PTX) resistance in the human ovarian cancer cell line A2780. Proc Am Assoc Cancer Res 36:456.

    Google Scholar 

  43. Mallarino MC, Duran GE, Dumontet CM, Sikic BI (1995) Mechanisms of resistance in a human sarcoma cell line continuously selected with paclitaxel (Taxol, TAX) and SDZ PSC 833. Proc Am Assoc Cancer Res 36:320.

    Google Scholar 

  44. Schibler MJ, Barlow SB, Cabrai F (1989) Elimination of permeability mutants from selections for drug resistance in mammalian cells. FASEB J 3:163–168.

    PubMed  CAS  Google Scholar 

  45. Jaffrezou J-P, Jordan M, Tsuchiya E, Wilson L, Sikic BI (1994) Novel drug resistance in human leukemic cell lines double-selected with SDZ PSC 833 and vinblastine or taxol. Proc Am Assoc Cancer Res 35:342.

    Google Scholar 

  46. Christen RD, Jekunen AP, Jones JA, Thiebaut FB, Shalinsky DR, Howell SB (1992) Modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacological alteration of microtubule function. Proc Am Assoc Cancer Res 33:535.

    Google Scholar 

  47. Jekunen AP, Christen R, Shalinsky D, Howell S (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69:299–306.

    PubMed  CAS  Google Scholar 

  48. Rixe O, Alvarez M, Miskley L, Ly H, Parker R, Tsokos M, Reed E, Fojo T (1993) Cisplatin (CP) resistance is multifactorial and includes changes in cytoskeletal distribution and dynamics. Proc Am Assoc Cancer Res 34:406.

    Google Scholar 

  49. Dietel M, Arps H, Lage H, Niendorf A (1990) Membrane vesicle formation due to aquired mitoxantrone resistance in human gastric carcinoma cell line EPG85–257. Cancer Res 50:6100–6106.

    PubMed  CAS  Google Scholar 

  50. Seidel A, Nickelsen M, Brandt I, Heinemann G, Dietel M (1991) Pathology and morphology of vesicular transport in drug-resistant tumor cells. J Cancer Res Clin Oncol 117(Suppl III):S90.

    Google Scholar 

  51. Speicher LA, Sheridan VR, Tew KD (1991) Human prostatic carcinoma cell (DU 145) resistance to antimitotic drugs. Proc Am Assoc Cancer Res 32:330.

    Google Scholar 

  52. Cabrai F, Sobel M, Gottesman M (1980) CHO mutants resistant to colchicine, colcemid or griseofulvine have an altered b-tubulin. Cell 20:29–36.

    Google Scholar 

  53. Keates R, Sarangi F, Ling V (1981) Structural and functional alterations in microtubule protein from Chinese hamster ovary cell mutants. Proc Natl Acad Sci USA 78:5638–5642.

    PubMed  CAS  Google Scholar 

  54. Cleveland D, Lopata M, Sherline P, Kirschner M (1981) Unpolymerized tubulin modulates the level of tubulin mRNAs. Cell 25:537–546.

    PubMed  CAS  Google Scholar 

  55. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC (1993) Glutathione depletion by L-butathione sulfoximine antagonizes taxol cytotoxicity. Cancer Res 53:2066–2070.

    PubMed  CAS  Google Scholar 

  56. Hamaguchi K, Godwin AK, Chapman JD, Yakushiji M, Hamilton TC (1993) The multidrugresistance phenotype of ovarian cancer cells with high primary cisplatin resistance correlates with elevated glutathione levels. Proc Am Assoc Cancer Res 34:306.

    Google Scholar 

  57. Kelland LR, Abel G (1992) Circumvention of cisplatin (acquired) resistance in an in vitro panel of human ovarian carcinoma cell lines by Taxotere (RP56976). Br J Cancer 65(Suppl 16):20.

    Google Scholar 

  58. Lowe SC, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967.

    PubMed  CAS  Google Scholar 

  59. Rouby Se, Thomas A, Costin D, Rosenberg CR, Potmesil M (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/ MDR3 gene expression. Blood 82:3452–3459.

    PubMed  Google Scholar 

  60. Lee F, Fairchild C, Long B (1994) Chemosensitivity to paclitaxel as a function of the p53 phenotype. Proc Am Assoc Cancer Res 35:419.

    Google Scholar 

  61. Wahl A, Donaldson K, Fairchild C, Lee F, Foster S, Galloway D, Demers G (1996) Loss of normal p53 functions confers sensitization to Taxol by increasing GZ/M arrest and apoptosis. Nature Medicine 2:72–79.

    PubMed  CAS  Google Scholar 

  62. Cross SA, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ (1995) A p53-dependent mouse spindle checkpoint. Science 267:1353–1356.

    PubMed  CAS  Google Scholar 

  63. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP (1994) Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54:3253–3259.

    PubMed  CAS  Google Scholar 

  64. Sumantran V, Ealovega M, Nunez G, Clarke M, Wicha M (1995) Overexpression of Bcl-xs sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55:2507–2510.

    PubMed  CAS  Google Scholar 

  65. Delaprote C, Larsen AK, Dautry F, Jacquemin-Sablon A (1991) Influence of myc overexpression of the phenotypic properties of Chinese hamster lung cells resistant to antitumor agents. Exp Cell Res 197:176–182.

    Google Scholar 

  66. Seidman A, Crown J, Reichman B (1993) Lack of clinical cross-resistance of Taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 12:53.

    Google Scholar 

  67. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdf J, O’shaughnessy J, Balis FM, Chabner BA (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621–1629.

    PubMed  CAS  Google Scholar 

  68. Gianni L, Capri G, Munzone E, Straneo M (1994) Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 21(Suppl 8):29–33.

    PubMed  CAS  Google Scholar 

  69. Eck L, Pavich D, Fruehauf JP (1993) MDR-1 expression by human ovarian tumors is associated with taxol resistance. Proc Am Assoc Cancer Res 34:232.

    Google Scholar 

  70. Uziely B, Delaflor-Weiss E, Lenz H, Groshan S, Jeffers S, Watkins K, Danenberg K, Russell C, Leichman G, Muggia F, Press M (1994) Paclitaxel (Taxol) in refractory breast cancer: Response correlates with low levels of MDR1 gene expression. Proc Am Soc Clin Oncol 13:75.

    Google Scholar 

  71. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jatte ES, Steinberg SM, Goldspiel BR, Cheson BD (1995) Phase II study of paclitaxel in relapsed non-Hodgkin’s lymphomas. J Clin Oncol 13:381–386.

    PubMed  CAS  Google Scholar 

  72. Wilson WH, Berg S, Kang YK (1993) Phase I–II study of Taxol 96-hr infusion in refractory lymphoma and breast cancer: Pharmacodynamics and analysis of multi-drug resistance (mdr-1). Proc Am Soc Clin Oncol 12:335.

    Google Scholar 

  73. Linn SC, Kuiper CM, Liefting AJ, Vermorken J, Pinedo H, Giaccone G (1993) MDR1 gene expression in anthracycline-resistant advanced breast cancer patients undergoing high dose Taxol treatment. Proc Am Soc Clin Oncol 12:87.

    Google Scholar 

  74. Riou J-F, Naudin A, Lavelle F (1992) Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Comm 187:164–170.

    PubMed  CAS  Google Scholar 

  75. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902–5910.

    PubMed  CAS  Google Scholar 

  76. Zaman GHR, Flens MJ, Leusden MRV, De Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91:8822–8826.

    PubMed  CAS  Google Scholar 

  77. Lee F, Sciandra J, Siemann D (1989) A study of the mechanism of resistance to Adriamicin in vivo. Glutathione metabolism, p-glycoprotein expression, and drug transport. Biochem Pharmacol 38:3697–3705.

    PubMed  CAS  Google Scholar 

  78. Fruehauf JP, Manetta A (1994) Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR-1 expression. Contrib Gynecol Obstet 19:39–52.

    PubMed  CAS  Google Scholar 

  79. Nicoletti M, Onorati L, Belotti D, Mangioni C, Casazza A, Giavazzi R (1995) Human ovarian carcinoma xenografts derived from paclitaxel (TAXOL)-treated patients. Proc Am Assoc Cancer Res 36:453.

    Google Scholar 

  80. Nicoletti M, Lucchini V, Massazza G, Abbott B, D’lncalci M, Giavazzi R (1993) Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann Oncol 4:151–155.

    PubMed  CAS  Google Scholar 

  81. O’Shaugnessy JA, Cowan KH, Nienhuis AW, McDonash KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D (1994) Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 5:891–911.

    Google Scholar 

  82. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK (1994) Differential cytotoxic effects of docetaxol in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169–82.

    PubMed  CAS  Google Scholar 

  83. Georgiadis M, Russell E, Johnson B (1994) Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity. Proc Am Assoc Cancer Res 35:341.

    Google Scholar 

  84. Liebmann JE, Cook JA, Lipschulta C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104–1109.

    PubMed  CAS  Google Scholar 

  85. Rose WC (1993) Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst Monogr 15:47–53.

    PubMed  Google Scholar 

  86. Fujimoto S (1994) Schedule dependency of IV-paclitaxel against sc-M 109 mouse lung cancer. Jpn J Cancer Chemother 21:671–677.

    CAS  Google Scholar 

  87. Zahn Z, Kang Y-K, Regis J, Shives B, Byrant G, Wilson W, Fojo AT, Bates S (1995) Taxol resistance: in vitro and in viro studies in breast cancer lymphoma. Proc Am Assoc Cancer Res 34:215.

    Google Scholar 

  88. Baguley BC, Marshall ES, Whittaker JR, Dotchin MC, Nixon J, McCrystal MR, Finlay GJ, Matthews JH, Holdaway KM, van Zijl P (1995) Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer 31A:230–237.

    PubMed  CAS  Google Scholar 

  89. Racker E, Wu L-T, Westcott D (1986) Use of slow calcium channel blockers to enhance inhibition by taxol of growth of drug-sensitive and drug-resistant Chinese hamster ovary cells. Cancer Treat Rep 70:275–278.

    PubMed  CAS  Google Scholar 

  90. Jachez B, Nordmann R, Loor F (1993) Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporin SDZ PSC 833 and the cyclopeptolide SDZ 280–446. J Natl Cancer Inst 85:478–483.

    PubMed  CAS  Google Scholar 

  91. Yang JM, Sommers S, Hait WN (1994) Reversal of Taxol resistance in vitro and in vivo by transflupenthixol and cyclosporin A. Proc Am Assoc Cancer Res 35:355.

    Google Scholar 

  92. Husain HR, Rahman A (1994) Mechanism of interaction of Taxol with P-glycoprotein in multidrug resistant cells. Proc Am Assoc Cancer Res 35:357.

    Google Scholar 

  93. Drori S, Eytan G, Assaraf Y (1995) Potentiation of anticancer-drug cytotoxicity by multidrugresistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228:1020–1029.

    PubMed  CAS  Google Scholar 

  94. Fisher GA, Bartlett NL, Lum BL, Brophy NA, Duran GE, Ehsan MN (1994) Phase I trial of taxol (T) with high dose cyclosporine (CsA) as a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:144.

    Google Scholar 

  95. Lorenz W (1977) Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents Action 7:63–67.

    CAS  Google Scholar 

  96. Woodcock D, Jefferson S, Linsenmeyer M (1990) Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199–4203.

    PubMed  CAS  Google Scholar 

  97. Chervinsky D, Brecher ML, Hoelcle MJ (1992) Cremophor-EL reverses taxol cross-resistance in murine C1300 multidrug resistant neuroblastoma cells. Proc Am Assoc Cancer Res 33:477.

    Google Scholar 

  98. Chervinsky D, Brecher M, Hoelcle M (1993) Cremophor-EL enhances taxol efficacy in a multidrug resistant C-1300 neuroblastoma cell type. Anticancer Res 13:93–96.

    PubMed  CAS  Google Scholar 

  99. Fjallskog M-L, Frii L, Bergh J (1994) Paclitaxel-induced cytotoxicity. The effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur J Cancer 30:687–690.

    Google Scholar 

  100. Fairchild CR (1993) Reversal of taxol resistance in a multidrug resistant human colon carcinoma cell line in vitro by cremophor EL and Tween 80. Bristol Myers Squibb Internal Report 910028780.

    Google Scholar 

  101. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D (1993) Measurement of Cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85:1685–1690.

    PubMed  CAS  Google Scholar 

  102. Nygren P, Csoka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B, Brodin D, Tholander B, Krueger A, Lonnerholm G, Jakobsson A, Olsen L, Kristensen J, Larsson R (1995) The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer 71:478–81.

    PubMed  CAS  Google Scholar 

  103. Liebmann JE, Cook JA, Mitchell JB (1993) Cremophor EL, solvent for paclitaxel, and toxicity. Lancet 342:1428.

    PubMed  CAS  Google Scholar 

  104. Liebmann J, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1994) The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines. Cancer Chemother Pharmacol 33:331–339.

    PubMed  CAS  Google Scholar 

  105. Fujimoto S (1994) Study for modifying activity of solvents on antitumor activity of paclitaxel. Jpn J Cancer Chemother 21:665–670.

    CAS  Google Scholar 

  106. Rose WC (1992) Taxol: A review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs 3:311–321.

    PubMed  CAS  Google Scholar 

  107. Fjallskog M-L, Frii L, Bergh J (1993) Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet 342:873.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Anna M. Casazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig R. Fairchild
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

  2. Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

  3. Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Casazza, A.M., Fairchild, C.R. (1996). Paclitaxel (Taxol®) Mechanisms of Resistance. In: Hait, W.N. (eds) Drug Resistance. Cancer Treatment and Research, vol 87. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1267-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1267-3_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8540-3

  • Online ISBN: 978-1-4613-1267-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation